Overview

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Biosciences International Sàrl
Incyte Corporation

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab